Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 383

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 383
---
 remain with ParentCo after the Business Combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation proceeding with the Business Combination, but we do not believe that this will be a determining factor in our decision to proceed with the Business Combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. For more information about the interests of Sponsor, directors and officers in the Business Combination, see the section titled “ Proposal No. 1 — The Business Combination Proposal — Interests of Certain Persons in the Business Combination. ”

<div align='center'>206</div>

TABLE OF CONTENTS

MANAGEMENT OF PARENTCO FOLLOWING THE BUSINESS COMBINATION The following sets forth certain information, as of January 2, 2025, concerning the persons who are expected to serve as directors and executive officers of ParentCo following the consummation of the Business Combination and assuming the election of the nominees at the Special Meeting as set forth in “ Election of Directors Proposal ”.

| Name                           | ​ | ​ | Age | ​ | ​ | Position                             | ​ |
| Chris Kim                      | ​ | ​ |  65 | ​ | ​ | Chief Executive Officer and Director | ​ |
| Scott Dam                      | ​ | ​ |  45 | ​ | ​ | Chief Financial Officer              | ​ |
| Byong C. Yoo, PhD              | ​ | ​ |  52 | ​ | ​ | Chief Science Officer                | ​ |
| Sang-jin Daniel Lee, PhD       | ​ | ​ |  54 | ​ | ​ | Head of Research & Development       | ​ |
| Beom K. Choi                   | ​ | ​ |  50 | ​ | ​ | Chief Technology Officer             | ​ |
| Eun Sook Lee, MD, PhD(1)(2)(3) | ​ | ​ |  61 | ​ | ​ | Independent Director                 | ​ |
| Nicholas Fernandez(1)(2)(3)    | ​ | ​ |  40 | ​ | ​ | Independent Director                 | ​ |
| Ji Yeon Baek(1)(2)(3)          | ​ | ​ |  53 | ​ | ​ | Independent Director                 | ​ |

(1) Member of the Audit Committee. (2) Member of the Nominating and Corporate Governance Committee. (3) Member of the Compensation Committee. Executive Officers Mr. Chris Kim, JD